Richard Murphy

Rich is Vice President of Intellectual Property at Synthekine and has more than 20 years of experience in biotechnology patent prosecution, litigation and licensing. Prior to joining Synthekine, he was in private practice providing strategic patent guidance for a number of biotechnology companies in the San Francisco, San Diego and Los Angeles areas. His experience includes the management of intellectual property portfolios for major pharmaceutical companies. As associate vice president of intellectual property for Sanofi-Pasteur, he was responsible for oversight of the Fluzone® influenza vaccine franchise. At Schering-Plough (now Merck), he was the Chief Patent Counsel for their gene therapy subsidiary, Canji, and responsible for due diligence and in-licensing for Schering-Plough Research Institute. He began his career in intellectual property at Eli Lilly and Company where, in addition to patent prosecution, he was extensively involved in due diligence and licensing and oversight of complex patent litigation matters. Rich received his B.S. in biochemistry from the University of Michigan, Ann Arbor, and his law degree from DePaul University. He is a member of the State Bar of California, the Indiana State Bar, the Court of Appeals for the Federal Circuit, and he is a registered patent attorney with the United States Patent and Trademark Office.